DE69209486D1 - Stabilisierte pharmaceutische Zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human IL-2 umfasst und Verfahren zu ihrer Herstellung - Google Patents

Stabilisierte pharmaceutische Zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human IL-2 umfasst und Verfahren zu ihrer Herstellung

Info

Publication number
DE69209486D1
DE69209486D1 DE69209486T DE69209486T DE69209486D1 DE 69209486 D1 DE69209486 D1 DE 69209486D1 DE 69209486 T DE69209486 T DE 69209486T DE 69209486 T DE69209486 T DE 69209486T DE 69209486 D1 DE69209486 D1 DE 69209486D1
Authority
DE
Germany
Prior art keywords
recombinant human
glycocylated
preparation
pharmaceutical composition
stabilized pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69209486T
Other languages
English (en)
Other versions
DE69209486T2 (de
Inventor
Bruno Maneglier
Bernard Voncken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Publication of DE69209486D1 publication Critical patent/DE69209486D1/de
Application granted granted Critical
Publication of DE69209486T2 publication Critical patent/DE69209486T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69209486T 1991-12-12 1992-12-11 Stabilisierte pharmaceutische Zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human IL-2 umfasst und Verfahren zu ihrer Herstellung Expired - Lifetime DE69209486T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9115418A FR2684878B1 (fr) 1991-12-12 1991-12-12 Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.

Publications (2)

Publication Number Publication Date
DE69209486D1 true DE69209486D1 (de) 1996-05-02
DE69209486T2 DE69209486T2 (de) 1996-09-12

Family

ID=9419958

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69209486T Expired - Lifetime DE69209486T2 (de) 1991-12-12 1992-12-11 Stabilisierte pharmaceutische Zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human IL-2 umfasst und Verfahren zu ihrer Herstellung

Country Status (18)

Country Link
US (1) US5340574A (de)
EP (1) EP0554634B1 (de)
JP (1) JP3291340B2 (de)
KR (1) KR930012023A (de)
AT (1) ATE135917T1 (de)
AU (1) AU662940B2 (de)
CA (1) CA2085142A1 (de)
DE (1) DE69209486T2 (de)
DK (1) DK0554634T3 (de)
ES (1) ES2084965T3 (de)
FR (1) FR2684878B1 (de)
GR (1) GR3019440T3 (de)
HU (1) HU218103B (de)
IL (1) IL103862A (de)
MX (1) MX9207199A (de)
RU (1) RU2107511C1 (de)
UA (1) UA26898C2 (de)
ZA (1) ZA929627B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018119A1 (fr) * 1997-10-03 1999-04-15 Shionogi & Co., Ltd. Procede de lyophilisation de proteines
PL211886B1 (pl) * 1999-10-04 2012-07-31 Novartis Vaccines & Diagnostic Stabilizowana ciekła kompozycja farmaceutyczna, sposób zwiększania trwałości polipeptydu, sposób zwiększania trwałości podczas przechowywania kompozycji, sucha postać kompozycji oraz preparat zawierający kompozycję
PT1599222E (pt) 2003-01-08 2009-06-12 Novartis Vaccines & Diagnostic Composições aquosas estabilizadas que contêm um inibidor da via do factor tecidular (tfpi) ou uma variante do inibidor da via do factor tecidular
JP2008501639A (ja) * 2004-04-23 2008-01-24 ノベシン リミテッド タンパク質を安定化、保護及び可溶化させるための方法及びキット
RU2588658C2 (ru) * 2010-04-27 2016-07-10 ЭсСиАйЭл Текнолоджи ГмбХ Стабильные водные композиции белка mia/cd-rap

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251001C (de) *
FR353150A (fr) * 1905-04-08 1905-09-04 Gerardo Caffaro Compteurs à gaz
FR452598A (fr) * 1912-12-26 1913-05-19 Lanston Monotype Corp Ltd Perfectionnements apportés aux machines servant à la composition typographique
WO1985004328A1 (en) * 1984-03-28 1985-10-10 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
EP0158487B1 (de) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stabile Interleukin-2-Zusammensetzung
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5204094A (en) * 1991-01-17 1993-04-20 Roussel Uclaf Treatment of pneumothorax

Also Published As

Publication number Publication date
AU662940B2 (en) 1995-09-21
HU218103B (hu) 2000-06-28
HUT63575A (en) 1993-09-28
US5340574A (en) 1994-08-23
ZA929627B (en) 1993-12-13
UA26898C2 (uk) 1999-12-29
DK0554634T3 (da) 1996-07-01
FR2684878B1 (fr) 1994-02-11
ES2084965T3 (es) 1996-05-16
GR3019440T3 (en) 1996-06-30
IL103862A (en) 1997-02-18
FR2684878A1 (fr) 1993-06-18
IL103862A0 (en) 1993-04-04
JP3291340B2 (ja) 2002-06-10
ATE135917T1 (de) 1996-04-15
MX9207199A (es) 1993-07-01
JPH05345728A (ja) 1993-12-27
HU9203925D0 (en) 1993-03-29
RU2107511C1 (ru) 1998-03-27
EP0554634A1 (de) 1993-08-11
KR930012023A (ko) 1993-07-20
DE69209486T2 (de) 1996-09-12
AU3004192A (en) 1993-06-17
CA2085142A1 (fr) 1993-06-13
EP0554634B1 (de) 1996-03-27

Similar Documents

Publication Publication Date Title
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
HUT51254A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient
EP0693924A4 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
IL109403A0 (en) Oral drug delivery compositions and methods
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
HUT48609A (en) Process for producing kumaran derivatives and pharmaceutical compositions comprising same as active ingredient
HUT58060A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
IT1241997B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
NZ227004A (en) Pharmaceutical composition containing melphalan hydrochloride
EP0340333A3 (en) Novel physiologically active polypeptide and pharmaceutical composition
HUT56856A (en) Process for producing biologically active stable somatotropins and pharmaceutical compositions comprising same asa active ingredient
ES2009215A6 (es) Procedimiento de preparar un derivado de interleucina-1beta.
IT1255723B (it) Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
IL95618A0 (en) Recombinant aprotinin variants,their preparation and medicaments containing them
DE69209486D1 (de) Stabilisierte pharmaceutische Zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human IL-2 umfasst und Verfahren zu ihrer Herstellung
HUT49370A (en) Process for producing polypeptides and pharmaceutical compositions comprising same as active ingredient
HUT49598A (en) Process for producing chromone derivatives and pharmaceutical compositions comprising same as active ingredient
IL88998A0 (en) Novel amino acid glycerides,processes for their preparation,and pharmaceutical compositions containing them
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
HUT52522A (en) Process for producing imidazol-substituted peptide derivatives and pharmaceutical compositions containing them as active components
EP0348664A3 (de) Monoacetoacetine enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Tumoren
HUT53121A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
ATE102934T1 (de) Fluorierte flavon-essigsaeure.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: HOECHST MARION ROUSSEL, PUTEAUX, FR

8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY CEDEX, FR

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

R071 Expiry of right

Ref document number: 554634

Country of ref document: EP